Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Jade Biosciences, Inc. has received an average recommendation of "Moderate Buy" from five analysts, with one analyst issuing a sell rating and four others recommending a buy.
• The company's average price target among brokers is $19.00, with some analysts suggesting values ranging from $14.00 to $28.00.
• In its latest earnings report, Jade Biosciences missed the consensus estimate, reporting ($0.86) earnings per share compared to the expected ($0.43).

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) have been given an average rating of "Moderate Buy" by the five ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $19.00.

JBIO has been the topic of several analyst reports. BTIG Research assumed coverage on shares of Jade Biosciences in a report on Thursday. They issued a "buy" rating and a $28.00 target price on the stock. Guggenheim raised shares of Jade Biosciences from a "neutral" rating to a "buy" rating and set a $14.00 price objective on the stock in a report on Monday, June 16th. Weiss Ratings reissued a "sell (e-)" rating on shares of Jade Biosciences in a report on Wednesday. Wedbush boosted their price objective on shares of Jade Biosciences from $17.00 to $18.00 and gave the stock an "outperform" rating in a report on Thursday, August 14th. Finally, Wall Street Zen downgraded shares of Jade Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, August 16th.

Jade Biosciences Trading Up 0.4%

Shares of NASDAQ:JBIO opened at $9.08 on Thursday. The stock has a market capitalization of $296.25 million, a P/E ratio of -0.30 and a beta of 1.05. The company has a 50-day moving average price of $7.79. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $105.00.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.43).

Institutional Trading of Jade Biosciences

Several large investors have recently modified their holdings of JBIO. Frazier Life Sciences Management L.P. acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $17,703,000. Versant Venture Management LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $15,243,000. Soleus Capital Management L.P. acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $7,959,000. Geode Capital Management LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $6,759,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $5,306,000.

About Jade Biosciences

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.